The DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.
Masitinib is a broad coronavirus 3CL inhibitor that blocks replication of SARS-CoV-2
Open accessAbstract
Targeting the main protease of SARS-CoV-2: Inside host cells, the RNA genome of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is translated into two polyproteins that are cleaved to give the individual viral proteins. The main viral protease, known as Mpro or 3CLpro, plays a key role in these cleavages, making it an important drug target. Drayman et al . identified eight drugs that target 3CLpro from a library of 1900 clinically safe drugs. Because of the challenge of working with SARS-CoV-2, they started by screening for drugs that inhibit the replication of a human coronavirus that causes the common cold. They then evaluated the top hits for inhibiting SARS-CoV-2 replication and for inhibiting 3CLpro. Masitinib, a broad antiviral, inhibited the main proteases of coronaviruses and picornaviruses and was effective in reducing SARS-CoV-2 replication in mice. —VV
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Coot : model-building tools for molecular graphics
Emsley, P., & Cowtan, K. (2004) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444904019158 · Cited by 30,571
MolProbity : all-atom structure validation for macromolecular crystallography
Chen, V. B., Arendall, W. B., Headd, J. J., Keedy, D. A., Immormino, R. M., Kapral, G. J., Murray, L. W., Richardson, J. S., & Richardson, D. C. (2010) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444909042073 · Cited by 14,115
Yang, X., Yu, Y., Xu, J., Shu, H., Xia, J., Liu, H., Wu, Y., Zhang, L., Yu, Z., Fang, M., et al. (2020) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(20)30079-5 · Cited by 10,066
Remdesivir for the Treatment of Covid-19 — Final Report
Beigel, J. H., Tomashek, K. M., Dodd, L. E., Mehta, A. K., Zingman, B. S., Kalil, A. C., Hohmann, E., Chu, H. Y., Luetkemeyer, A., Kline, S., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2007764 · Cited by 7,267
A SARS-CoV-2 protein interaction map reveals targets for drug repurposing
Gordon, D. E., Jang, G. M., Bouhaddou, M., Xu, J., Obernier, K., White, K. M., O’Meara, M. J., Rezelj, V. V., Guo, J. Z., Swaney, D. L., et al. (2020) · Nature · doi:10.1038/s41586-020-2286-9 · Cited by 4,405
Self-citationStructure of Mpro from SARS-CoV-2 and discovery of its inhibitors
Jin, Z., Du, X., Xu, Y., Deng, Y., Liu, M., Zhao, Y., Zhang, B., Li, X., Zhang, L., Peng, C., et al. (2020) · Nature · doi:10.1038/s41586-020-2223-y · Cited by 4,358
Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19
Blanco-Melo, D., Nilsson-Payant, B. E., Liu, W.-C., Uhl, S., Hoagland, D., Møller, R., Jordan, T. X., Oishi, K., Panis, M., Sachs, D., et al. (2020) · Cell · doi:10.1016/j.cell.2020.04.026 · Cited by 4,222
The determination of enzyme inhibitor constants
Dixon, M. (1953) · Biochemical Journal · doi:10.1042/bj0550170 · Cited by 4,069
Molecular replacement with MOLREP
Vagin, A., & Teplyakov, A. (2010) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444909042589 · Cited by 3,604
Emerging coronaviruses: Genome structure, replication, and pathogenesis
Chen, Y., Liu, Q., & Guo, D. (2020) · Journal of Medical Virology · doi:10.1002/jmv.25681 · Cited by 3,062
Zhang, L., Lin, D., Sun, X., Curth, U., Drosten, C., Sauerhering, L., Becker, S., Rox, K., & Hilgenfeld, R. (2020) · Science · doi:10.1126/science.abb3405 · Cited by 2,895
Minor, W., Cymborowski, M., Otwinowski, Z., & Chruszcz, M. (2006) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444906019949 · Cited by 2,099
Coronavirus Main Proteinase (3CL pro ) Structure: Basis for Design of Anti-SARS Drugs
Anand, K., Ziebuhr, J., Wadhwani, P., Mesters, J. R., & Hilgenfeld, R. (2003) · Science · doi:10.1126/science.1085658 · Cited by 1,728
Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main protease
Dai, W., Zhang, B., Jiang, X.-M., Su, H., Li, J., Zhao, Y., Xie, X., Jin, Z., Peng, J., Liu, F., et al. (2020) · Science · doi:10.1126/science.abb4489 · Cited by 1,478
Lethal Infection of K18- hACE2 Mice Infected with Severe Acute Respiratory Syndrome Coronavirus
McCray, P. B., Pewe, L., Wohlford-Lenane, C., Hickey, M., Manzel, L., Shi, L., Netland, J., Jia, H. P., Halabi, C., Sigmund, C. D., et al. (2007) · Journal of Virology · doi:10.1128/jvi.02012-06 · Cited by 1,010
Viruses and bacteria in the etiology of the common cold
Mäkelä, M. J., Puhakka, T., Ruuskanen, O., Leinonen, M., Saikku, P., Kimpimäki, M., Blomqvist, S., Hyypiä, T., & Arstila, P. (1998) · Journal of Clinical Microbiology · doi:10.1128/jcm.36.2.539-542.1998 · Cited by 768
Discovery of SARS-CoV-2 antiviral drugs through large-scale compound repurposing
Riva, L., Yuan, S., Yin, X., Martin-Sancho, L., Matsunaga, N., Pache, L., Burgstaller-Muehlbacher, S., De Jesus, P. D., Teriete, P., Hull, M. V., et al. (2020) · Nature · doi:10.1038/s41586-020-2577-1 · Cited by 760
Anand, K. (2002) · The EMBO Journal · doi:10.1093/emboj/cdf327 · Cited by 618
Kneller, D. W., Phillips, G., O’Neill, H. M., Jedrzejczak, R., Stols, L., Langan, P., Joachimiak, A., Coates, L., & Kovalevsky, A. (2020) · Nature Communications · doi:10.1038/s41467-020-16954-7 · Cited by 474
Self-citationStructure of papain-like protease from SARS-CoV-2 and its complexes with non-covalent inhibitors
Osipiuk, J., Azizi, S.-A., Dvorkin, S., Endres, M., Jedrzejczak, R., Jones, K. A., Kang, S., Kathayat, R. S., Kim, Y., Lisnyak, V. G., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-21060-3 · Cited by 462
Self-citationFeline coronavirus drug inhibits the main protease of SARS-CoV-2 and blocks virus replication
Vuong, W., Khan, M. B., Fischer, C., Arutyunova, E., Lamer, T., Shields, J., Saffran, H. A., McKay, R. T., van Belkum, M. J., Joyce, M. A., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-18096-2 · Cited by 438
Masitinib (AB1010), a potent and selective tyrosine kinase inhibitor targeting KIT
Dubreuil, P., Letard, S., Ciufolini, M., Gros, L., Humbert, M., Castéran, N., Borge, L., Hajem, B., Lermet, A., Sippl, W., et al. (2009) · PLoS ONE · doi:10.1371/journal.pone.0007258 · Cited by 421
Genome-Scale Identification of SARS-CoV-2 and Pan-coronavirus Host Factor Networks
Schneider, W. M., Luna, J. M., Hoffmann, H.-H., Sánchez-Rivera, F. J., Leal, A. A., Ashbrook, A. W., Le Pen, J., Ricardo-Lax, I., Michailidis, E., Peace, A., et al. (2021) · Cell · doi:10.1016/j.cell.2020.12.006 · Cited by 400
A genome-wide CRISPR screen identifies host factors that regulate SARS-CoV-2 entry
Zhu, Y., Feng, F., Hu, G., Wang, Y., Yu, Y., Zhu, Y., Xu, W., Cai, X., Sun, Z., Han, W., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-21213-4 · Cited by 304
Masitinib is Safe and Effective for the Treatment of Canine Mast Cell Tumors
Hahn, K. A., Oglivie, G., Rusk, T., Devauchelle, P., Leblanc, A., Legendre, A., Powers, B., Leventhal, P. S., Kinet, J.-P., Palmerini, F., et al. (2008) · Journal of Veterinary Internal Medicine · doi:10.1111/j.1939-1676.2008.0190.x · Cited by 289
Xue, X., Yang, H., Shen, W., Zhao, Q., Li, J., Yang, K., Chen, C., Jin, Y., Bartlam, M., & Rao, Z. (2007) · Journal of Molecular Biology · doi:10.1016/j.jmb.2006.11.073 · Cited by 260
Genome-wide CRISPR screening identifies TMEM106B as a proviral host factor for SARS-CoV-2
Baggen, J., Persoons, L., Vanstreels, E., Jansen, S., Van Looveren, D., Boeckx, B., Geudens, V., De Man, J., Jochmans, D., Wauters, J., et al. (2021) · Nature Genetics · doi:10.1038/s41588-021-00805-2 · Cited by 225
Mora, J. S., Genge, A., Chio, A., Estol, C. J., Chaverri, D., Hernández, M., Marín, S., Mascias, J., Rodriguez, G. E., Povedano, M., et al. (2020) · Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration · doi:10.1080/21678421.2019.1632346 · Cited by 220
Identification of SARS-CoV-2 3CL Protease Inhibitors by a Quantitative High-Throughput Screening
Zhu, W., Xu, M., Chen, C. Z., Guo, H., Shen, M., Hu, X., Shinn, P., Klumpp-Thomas, C., Michael, S. G., & Zheng, W. (2020) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.0c00108 · Cited by 219
The development of Coronavirus 3C-Like protease (3CLpro) inhibitors from 2010 to 2020
Liu, Y., Liang, C., Xin, L., Ren, X., Tian, L., Ju, X., Li, H., Wang, Y., Zhao, Q., Liu, H., et al. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112711 · Cited by 170
The journey of remdesivir: from Ebola to COVID-19
Pardo, J., Shukla, A. M., Chamarthi, G., & Gupte, A. (2020) · Drugs in Context · doi:10.7573/dic.2020-4-14 · Cited by 166
Recovery of an arenavirus entirely from RNA polymerase I/II-driven cDNA
Flatz, L., Bergthaler, A., de la Torre, J. C., & Pinschewer, D. D. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0600652103 · Cited by 162
High-throughput protein purification and quality assessment for crystallization
Kim, Y., Babnigg, G., Jedrzejczak, R. P., Eschenfeldt, W. H., Li, H., Maltseva, N., Hatzos-Skintges, C., Gu, M., Makowska-Grzyska, M., Wu, R., et al. (2011) · Methods · doi:10.1016/j.ymeth.2011.07.010 · Cited by 150
Self-citationLee, C., Kuo, C., Ko, T., Hsu, M.-F., Tsui, Y.-C., Chang, S., Yang, S., Chen, S.-J., Chen, H., Hsu, M., et al. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m807947200 · Cited by 143
Self-citationKilianski, A., Mielech, A. M., Deng, X., & Baker, S. C. (2013) · Journal of Virology · doi:10.1128/jvi.02105-13 · Cited by 142
Self-citationMasitinib treatment in patients with progressive multiple sclerosis: a randomized pilot study
Vermersch, P., Benrabah, R., Schmidt, N., Zéphir, H., Clavelou, P., Vongsouthi, C., Dubreuil, P. C., Moussy, A., & Hermine, O. (2012) · BMC Neurology · doi:10.1186/1471-2377-12-36 · Cited by 140
Humbert, M. J. C., Frederic de, B. L. A. Y., Garcia, G., Prudhomme, A., Leroyer, C., Magnan, A., Tunon‐de‐Lara, J. M., Pison, C. M., Aubier, M., Charpin, D., et al. (2009) · Allergy · doi:10.1111/j.1398-9995.2009.02122.x · Cited by 138
Ghosh, A. K., Gong, G., Grum-Tokars, V. L., Mulhearn, D. C., Baker, S. C., Coughlin, M. M., Prabhakar, B. S., Sleeman, K., Johnson, M. E., & Mesecar, A. D. (2008) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2008.08.082 · Cited by 137
Self-citationDevelopment of a Fluorescence-Based, High-Throughput SARS-CoV-2 3CL pro Reporter Assay
Froggatt, H. M., Heaton, B. E., & Heaton, N. S. (2020) · Journal of Virology · doi:10.1128/jvi.01265-20 · Cited by 102
Self-citationDeng, X., John, S. E. S., Osswald, H. L., O’Brien, A., Banach, B. S., Sleeman, K., Ghosh, A. K., Mesecar, A. D., & Baker, S. C. (2014) · Journal of Virology · doi:10.1128/jvi.01528-14 · Cited by 100
Self-citationMasitinib (AB1010), from canine tumor model to human clinical development: Where we are?
Marech, I., Patruno, R., Zizzo, N., Gadaleta, C., Introna, M., Zito, A. F., Gadaleta, C. D., & Ranieri, G. (2013) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2013.12.011 · Cited by 90
Valle, J. R., Devaux, P., Hodge, G., Wegner, N. J., McChesney, M. B., & Cattaneo, R. (2007) · Journal of Virology · doi:10.1128/jvi.00923-07 · Cited by 87
Soria, J., Massard, C., Magné, N., Bader, T., Mansfield, C. D., Blay, J., Bui, B., Moussy, A., Hermine, O., & Armand, J. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2009.05.010 · Cited by 83
Masitinib for the treatment of mild to moderate Alzheimer’s disease
Folch, J., Petrov, D., Ettcheto, M., Pedrós, I., Abad, S., Beas-Zarate, C., Lazarowski, A., Marin, M., Olloquequi, J., Auladell, C., et al. (2015) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.2015.1045419 · Cited by 80
Lee, H., Mittal, A., Patel, K., Gatuz, J. L., Truong, L., Torres, J., Mulhearn, D. C., & Johnson, M. E. (2013) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2013.11.041 · Cited by 62
Self-citationOttaiano, A., Capozzi, M., Divitiis, C. D., Stefano, A. D., Botti, G., Avallone, A., & Tafuto, S. (2017) · Acta Oncologica · doi:10.1080/0284186x.2017.1288922 · Cited by 55
Ziegler, C. M., Eisenhauer, P. L., Bruce, E. A., Weir, M. E., King, B. R., Klaus, J. P., Krementsov, D. N., Shirley, D. J., Ballif, B. A., & Botten, J. (2016) · PLoS Pathogens · doi:10.1371/journal.ppat.1005501 · Cited by 46
Self-citationLee‐Fowler, T. M., Guntur, V. P., Dodam, J. R., Cohn, L. A., DeClue, A. E., & Reinero, C. R. (2012) · International Archives of Allergy and Immunology · doi:10.1159/000335122 · Cited by 45
Terwilliger, T. C., Read, R. J., Adams, P. D., Brünger, A. T., Afonine, P. V., Grosse‐Kunstleve, R. W., & Hung, L. (2012) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444912015636 · Cited by 42
Graham, N. R., Whitaker, A., Strother, C. A., Miles, A. K., Grier, D., McElvany, B. D., Bruce, E. A., Poynter, M. E., Pierce, K. K., Kirkpatrick, B. D., et al. (2020) · Clinical & Translational Immunology · doi:10.1002/cti2.1189 · Cited by 42
Self-citationA simplified cell-based assay to identify coronavirus 3CL protease inhibitorsPreprint
Resnick, S. J., Iketani, S., Hong, S. J., Zask, A., Liu, H., Kim, S. S., Melore, S., Nair, M. S., Huang, Y., Tay, N. E. S., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.08.29.272864 · Cited by 11
Cited by
Ma, C., Tan, H., Choza, J., Wang, Y., & Wang, J. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2021.10.026 · Cited by 86
Drug Combinations as a First Line of Defense against Coronaviruses and Other Emerging Viruses
White, J. M., Schiffer, J. T., Bender Ignacio, R. A., Xu, S., Kainov, D., Ianevski, A., Aittokallio, T., Frieman, M., Olinger, G. G., & Polyak, S. J. (2021) · mBio · doi:10.1128/mbio.03347-21 · Cited by 64
Tan, H., Ma, C., & Wang, J. (2022) · Medicinal Chemistry Research · doi:10.1007/s00044-022-02903-0 · Cited by 21
Metadata
- Authors
- Drayman, N., DeMarco, J. K., Jones, K. A., Azizi, S.-A., Froggatt, H. M., Tan, K., Maltseva, N. I., Chen, S., Nicolaescu, V., Dvorkin, S., Furlong, K., Kathayat, R. S., Firpo, M. R., Mastrodomenico, V., Bruce, E. A., Schmidt, M. M., Jedrzejczak, R., Muñoz-Alía, M. Á., Schuster, B., Nair, V., Han, K.-Y., O’Brien, A., Tomatsidou, A., Meyer, B., Vignuzzi, M., Missiakas, D., Botten, J. W., Brooke, C. B., Lee, H., Baker, S. C., Mounce, B. C., Heaton, N. S., Severson, W. E., Palmer, K. E., Dickinson, B. C., Joachimiak, A., Randall, G., & Tay, S.
- Venue
- Science
- Published
- 2021-08-20
- Volume
- 373
- Issue
- 6557
- Pages
- 931-936
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W3183900570
- Cited by
- 273
- References
- 51
- FWCI
- 16.73
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.